Recombinant Human Metalloreductase STEAP2 (STEAP2)-VLPs

What is the basic structure of STEAP2 protein?

STEAP2 is a six-transmembrane protein functioning as a metalloreductase. The human STEAP2 protein consists of 490 amino acid residues and contains conserved domains that facilitate its metalloreductase activity. The protein is primarily localized to the plasma membrane of prostate cells and the Golgi complex . Its structure includes transmembrane regions that facilitate electron transfer across membranes, with specific binding sites for NADPH, FAD, and heme groups that enable its reductive functions .

What are the primary functional mechanisms of STEAP2?

STEAP2 functions primarily as a NADPH-dependent ferric-chelate reductase, facilitating sequential transmembrane electron transfer. The protein uses NADPH from one side of the membrane to reduce Fe(3+) chelates bound on the opposite side. The electron transfer pathway proceeds from NADPH to FAD, then to heme, and finally to the Fe(3+) chelate, resulting in its reduction to Fe(2+). Additionally, STEAP2 can reduce Cu(2+) to Cu(1+), suggesting broader metal ion reduction capabilities . This metalloreductase activity may contribute to iron and copper homeostasis in cells where STEAP2 is expressed.

How does STEAP2 differ from other STEAP family members?

STEAP2 shares structural homology with other STEAP family members but has distinct expression patterns and potentially specialized functions. Phylogenetic analysis indicates evolutionary relationships between STEAP proteins across species, with maximum likelihood tree analysis showing bootstrap values that support the divergence of STEAP2 from other family members . Unlike some other STEAP family members, STEAP2 is highly expressed in prostate cancer and osteosarcoma tissues, making it a more specific biomarker for these cancer types .

What are VLPs and how are they relevant to STEAP2 research?

Virus-Like Particles (VLPs) are self-assembling protein structures that mimic viruses but lack viral genetic material, making them non-infectious. When STEAP2 is incorporated into VLPs, the resulting STEAP2-VLPs present multiple copies of the protein in its native conformation, potentially preserving critical epitopes and functional domains. This approach enables researchers to study STEAP2 in a more physiologically relevant context compared to soluble recombinant proteins, particularly for analyzing membrane-associated functions and developing targeted therapeutics or vaccines.

What expression systems are optimal for recombinant STEAP2 production?

Several expression systems have been successfully employed for recombinant STEAP2 production, each with specific advantages. For structural and functional studies, HEK-293 cells offer proper post-translational modifications and folding of human STEAP2, resulting in protein with >90% purity as determined by Bis-Tris PAGE and analytical SEC . For large-scale production of specific domains, E. coli systems can be used, though they may require refolding protocols to achieve functional protein. Cell-free protein synthesis (CFPS) systems have also proven effective for producing STEAP2 with approximately 70-80% purity, offering advantages in speed and scalability . The choice of expression system should align with research objectives—mammalian systems for structural studies, bacterial systems for high-yield applications, and CFPS for rapid screening.

What purification strategies yield the highest quality STEAP2 protein?

High-quality STEAP2 purification typically involves affinity chromatography followed by additional refinement steps. For Strep-tagged STEAP2, one-step Strep-tag purification yields 70-80% purity as determined by SDS-PAGE, Western Blot, and analytical SEC . His-tagged variants can achieve >97% purity using nickel affinity chromatography followed by size exclusion chromatography. The purification protocol should include detergent optimization since STEAP2 is a transmembrane protein—common detergents include DDM, LMNG, or GDN at concentrations that maintain protein stability without causing aggregation. For applications requiring higher purity, ion exchange chromatography can be incorporated as an intermediate step between affinity capture and size exclusion.

How can researchers verify the functional integrity of purified STEAP2?

Functional verification of purified STEAP2 requires assessment of both structural integrity and enzymatic activity. Western blotting using specific anti-STEAP2 antibodies confirms protein identity and integrity . For metalloreductase activity, researchers should employ a spectrophotometric assay measuring NADPH consumption coupled with the reduction of ferric iron complexes (typically using ferrozine as an indicator). Active STEAP2 will show concentration-dependent rates of NADPH oxidation correlated with ferrous iron production. Circular dichroism spectroscopy can confirm proper protein folding, while thermal shift assays assess stability under various buffer conditions. Additionally, proper membrane insertion for transmembrane domains can be verified using liposome reconstitution followed by protease protection assays.

What methods are effective for generating STEAP2-VLPs?

Generating STEAP2-VLPs typically involves co-expression of STEAP2 with viral structural proteins that drive VLP assembly. An effective approach uses mammalian expression systems (typically HEK293 or ExpiCHO cells) transfected with vectors encoding both STEAP2 and viral structural proteins such as those from hepatitis B virus, human papillomavirus, or bacteriophage Qβ. Alternatively, baculovirus expression systems can be employed for higher yields. Purification typically involves density gradient ultracentrifugation followed by size exclusion chromatography. Successful incorporation of STEAP2 into VLPs can be verified through Western blotting, electron microscopy, and dynamic light scattering to confirm particle size distribution (typically 20-100 nm depending on the VLP platform used).

How can STEAP2 be used as a biomarker in cancer research?

STEAP2 serves as a valuable biomarker in cancer research, particularly for prostate cancer and osteosarcoma. Immunohistochemical staining demonstrates STEAP2 expression at cell-cell junctions of prostate cancer cells, and its differential expression between normal and cancerous tissues makes it a promising diagnostic marker . Researchers can employ various approaches to leverage STEAP2 as a biomarker, including quantitative PCR to assess mRNA expression levels, Western blotting for protein quantification, and immunohistochemistry for tissue localization. Research indicates that upregulation of STEAP2 in osteosarcoma tissues positively correlates with malignant phenotypes and poor patient outcomes, enabling prognostic applications . For clinical validation, researchers should establish standardized scoring systems for STEAP2 expression and correlate findings with patient data through Kaplan-Meier analyses.

What knockdown strategies are most effective for studying STEAP2 function?

Several knockdown strategies have proven effective for studying STEAP2 function in cancer models. RNA interference using lentiviral vectors (LV-STEAP2-RNAi) has successfully reduced STEAP2 expression in osteosarcoma cell lines, with approximately 80% transfection efficiency achieved using a multiplicity of infection (MOI) of 50 . CRISPR-Cas9 genome editing offers an alternative approach for complete STEAP2 knockout, particularly valuable for long-term studies. The effectiveness of knockdown should be verified through multiple methods including qRT-PCR, Western blot, and immunocytochemistry . Functional readouts following STEAP2 knockdown include assessing changes in cell proliferation, migration (using wound healing assays), invasion (using Transwell assays), and apoptosis rates (using flow cytometry with Annexin V staining).

How does STEAP2 contribute to epithelial-mesenchymal transition in cancer progression?

STEAP2 promotes epithelial-mesenchymal transition (EMT) primarily through activation of the PI3K/AKT/mTOR signaling axis. Research demonstrates that STEAP2 expression induces EMT and facilitates cancer cell infiltration and migration in osteosarcoma models . When investigating this mechanism, researchers should assess typical EMT markers including decreased E-cadherin expression and increased expression of N-cadherin, vimentin, and transcription factors such as Snail and Twist. Phosphorylation levels of key signaling proteins (PI3K, AKT, mTOR) should be quantified by Western blotting to confirm pathway activation. Treatment with pathway inhibitors (e.g., LY294002 for PI3K, rapamycin for mTOR) can confirm the dependence of STEAP2-induced EMT on this signaling cascade. Importantly, research shows that the relationship between STEAP2 and other proteins like EFEMP2 affects invasive potential, with EFEMP2-overexpressing cells exhibiting reduced EMT following STEAP2 inhibition .

What experimental approaches can assess STEAP2-VLP interactions with immune cells?

Assessing STEAP2-VLP interactions with immune cells requires multiple complementary approaches. Flow cytometry using fluorescently labeled STEAP2-VLPs can quantify binding to various immune cell populations (dendritic cells, macrophages, B cells) and identify specific receptors through competitive binding assays. Confocal microscopy with dual-labeled particles confirms internalization and intracellular trafficking. Functional immune responses can be measured through cytokine profiling (ELISA or multiplex assays), activation marker expression (CD80, CD86, MHC-II), and T-cell stimulation assays (measuring proliferation and cytokine production). For mechanistic studies, inhibitors of various uptake pathways (e.g., cytochalasin D for phagocytosis, chlorpromazine for clathrin-mediated endocytosis) help delineate the mode of STEAP2-VLP processing by immune cells.

What molecular docking approaches have identified potential STEAP2 inhibitors?

Molecular docking approaches have successfully identified potential STEAP2 inhibitors through computational screening of drug candidates. One comprehensive study used AutoDock Vina to dock a modeled STEAP2 3D structure against 2,466 FDA-approved drug candidates . This rigid receptor, flexible ligand approach identified promising drug candidates with high binding energies. Triptorelin showed the highest binding energy at -12.1 kcal/mol, followed by leuprolide at -11.2 kcal/mol . The study employed multiple modeling engines (I-TASSER, RaptorX, SWISS-MODEL) to generate STEAP2 homology models, which were then evaluated using various structural model assessment tools including ProSa, QMEAN, Rampage, DOPE scores, and RMSD calculations . For researchers conducting similar studies, prioritizing compounds that interact with conserved domains identified through multiple sequence alignment and phylogenetic analysis will yield more reliable candidates.

How can STEAP2-VLPs be utilized for cancer immunotherapy approaches?

STEAP2-VLPs offer multiple advantages for cancer immunotherapy due to their particulate nature and ability to present STEAP2 epitopes in their native conformation. As immunogens, STEAP2-VLPs can stimulate both humoral and cellular immune responses against STEAP2-expressing tumors without requiring adjuvants typical of soluble protein vaccines. Researchers can enhance efficacy by incorporating immunostimulatory molecules (e.g., CpG, poly I:C) either chemically coupled to VLPs or encapsulated within them. For adoptive cell therapy applications, dendritic cells pulsed with STEAP2-VLPs can efficiently process and present STEAP2 epitopes for T-cell stimulation. Evaluation protocols should include assessment of antibody titers, antibody-dependent cellular cytotoxicity, CD8+ T-cell responses (using ELISPOT or intracellular cytokine staining), and ultimately tumor challenge studies in appropriate animal models.

What is the role of STEAP2 in resistance to conventional cancer therapies?

STEAP2 may contribute to therapeutic resistance through several mechanisms that researchers should investigate systematically. As a metalloreductase, STEAP2 could alter the redox environment of cancer cells, potentially neutralizing oxidative stress induced by radiation or certain chemotherapeutics. Its role in promoting EMT, as demonstrated in osteosarcoma models , may contribute to a chemoresistant mesenchymal phenotype. Experimental approaches to study this phenomenon should include comparing STEAP2 expression levels before and after treatment in resistant versus sensitive cell lines, examining correlations between STEAP2 expression and treatment outcomes in patient cohorts, and assessing whether STEAP2 knockdown sensitizes cells to standard therapies. Additionally, researchers should investigate whether STEAP2 affects drug efflux pump expression or activity, and explore combination approaches where STEAP2 inhibition precedes conventional treatment.

How do STEAP2 expression patterns vary across cancer types and stages?

STEAP2 expression patterns show significant variation across cancer types and stages, requiring detailed characterization for targeted therapeutic development. In prostate cancer, STEAP2 expression correlates with disease progression and is significantly higher in cancerous tissues compared to normal prostate epithelium . Research in osteosarcoma demonstrates that STEAP2 upregulation positively correlates with malignant phenotypes and poor patient outcomes . When analyzing STEAP2 expression patterns, researchers should employ multiple methods including RNA-seq for transcriptional profiling, tissue microarrays for protein-level analysis across multiple samples, and single-cell approaches to identify specific STEAP2-expressing subpopulations. Correlation analyses should examine relationships between STEAP2 expression and clinical parameters including tumor stage, grade, metastatic status, and treatment response. Such comprehensive profiling helps identify patient populations most likely to benefit from STEAP2-targeted therapies.

What are the challenges in designing STEAP2-specific antibodies for research and therapeutic applications?

Designing STEAP2-specific antibodies presents several challenges due to its multi-transmembrane structure and potential homology with other STEAP family members. The extracellular loops of STEAP2 offer limited exposed epitopes, requiring careful epitope selection through computational prediction tools combined with structural analysis. Researchers should consider using synthetic peptides corresponding to extracellular domains or recombinant protein fragments for immunization. Phage display technology offers an alternative approach for generating highly specific antibodies. Cross-reactivity with other STEAP family members must be rigorously tested using ELISA, Western blotting, and immunohistochemistry on tissues with differential STEAP expression profiles. For therapeutic applications, antibody internalization capacity should be assessed to determine suitability for antibody-drug conjugate development, and immunogenicity testing should be conducted in appropriate models. Native conformation preservation is critical, making STEAP2-VLPs particularly valuable for antibody development.

How can researchers reconcile contradictory findings about STEAP2 function across different cancer models?

Contradictory findings about STEAP2 function across cancer models may stem from context-dependent effects related to genetic background, tissue origin, or experimental conditions. To reconcile such discrepancies, researchers should conduct systematic comparisons using standardized protocols across multiple cell lines representing different cancer types. Comprehensive molecular profiling (RNA-seq, proteomics) can identify co-factors or pathways that modify STEAP2 function in specific contexts. Isogenic cell models generated through CRISPR-Cas9 technology allow assessment of STEAP2 effects against matched genetic backgrounds. When analyzing published literature, researchers should critically evaluate methodological differences including STEAP2 expression levels (physiological versus overexpression), knockdown efficiency, assay timing, and endpoint measurements. Integration of data from patient-derived xenografts and clinical samples provides additional validation to determine which model systems most accurately reflect human disease.

What post-translational modifications affect STEAP2 function and localization?

Post-translational modifications (PTMs) of STEAP2 may significantly influence its function, localization, and protein-protein interactions. Although specific PTMs of STEAP2 are not extensively characterized in the provided search results, researchers should investigate several potential modifications: phosphorylation of cytoplasmic domains may regulate activity or protein interactions; glycosylation of extracellular domains may affect protein stability and recognition; and ubiquitination may control protein turnover and trafficking. Mass spectrometry approaches, including enrichment strategies for specific PTMs, can identify modification sites. Site-directed mutagenesis of predicted modification sites followed by functional assays can determine their significance. For trafficking studies, researchers should employ live-cell imaging with fluorescently tagged STEAP2 variants to track protein movement through cellular compartments. Proximity labeling techniques (BioID, APEX2) can map the interactome of differentially modified STEAP2 forms.

How do model systems for studying STEAP2-VLPs compare in their predictive value for clinical applications?

This comparative table highlights that while in vitro systems offer accessibility for initial studies, the predictive value increases with model complexity. For STEAP2-VLP development, researchers should employ a staged approach beginning with cell line screening, followed by organoid validation, and culminating in appropriate animal models that assess both efficacy and immunological responses.

What strategies address poor expression or solubility issues with recombinant STEAP2?

Poor expression or solubility of recombinant STEAP2 can be addressed through several strategies targeting protein production and extraction. For expression optimization, researchers should test different host systems—bacterial systems for cytoplasmic domains, insect cells for full-length protein, and mammalian cells for properly folded human STEAP2 . Expression can be enhanced by codon optimization for the host organism, using strong but controllable promoters, and optimizing growth conditions (temperature, induction timing, media composition). For solubility improvement, fusion tags (SUMO, MBP, TRX) can enhance folding, while detergent screening (beginning with mild detergents like DDM or LMNG) is critical for extracting this transmembrane protein. Alternative approaches include refolding from inclusion bodies or expressing truncated versions containing specific domains of interest. Cell-free protein synthesis systems also offer advantages for difficult-to-express proteins, with demonstrated success for STEAP2 .

How can researchers address inconsistent results in STEAP2 functional assays?

Inconsistent results in STEAP2 functional assays typically stem from variability in protein quality, assay conditions, or cellular context. To standardize STEAP2 quality, researchers should implement rigorous quality control measures including SEC-MALS to verify monodispersity, thermal shift assays to confirm stability, and activity assays to ensure functionality before experimental use. For metalloreductase activity assays, standardization is critical—researchers should control for metal ion contamination using chelating agents in buffers, standardize NADPH concentrations, and use internal controls. When working with cell-based assays, passage number effects can be minimized by establishing a master cell bank, and transfection efficiency variability can be addressed using selection markers or fluorescent reporters. Finally, biological replicates should use cells from different passages, and technical replicates should include positive and negative controls on each experimental plate to quantify and normalize for run-to-run variation.

What methods can validate the structural integrity of STEAP2 within VLPs?

Validating STEAP2 structural integrity within VLPs requires multiple complementary approaches examining both physical incorporation and conformational authenticity. Researchers should first confirm STEAP2 incorporation using Western blotting of purified VLPs, with quantification against protein standards to determine copy number per particle. Electron microscopy (negative staining and cryo-EM) visualizes particle morphology and can detect structural abnormalities. For conformational validation, binding assays using conformation-specific antibodies that recognize native epitopes can distinguish properly folded from misfolded STEAP2. Functional assays measuring metalloreductase activity of VLP preparations provide the most definitive evidence of structural integrity. Additionally, limited proteolysis followed by mass spectrometry can map exposed regions, while thermal stability assays comparing free STEAP2 to VLP-incorporated STEAP2 can reveal stabilization effects of the particle environment.

What are the major considerations when scaling up STEAP2-VLP production for preclinical studies?

Scaling up STEAP2-VLP production for preclinical studies presents several challenges requiring systematic optimization. The expression system must balance yield with product quality—while insect cell systems using baculovirus vectors often provide the highest yields, mammalian systems may produce more authentic post-translational modifications . Process parameters requiring optimization include cell density at infection/transfection, harvest timing, and culture supplements that enhance protein expression without compromising quality. Purification scaling involves transitioning from density gradients to more scalable methods like tangential flow filtration followed by chromatographic techniques. Quality control metrics must be established, including particle size distribution (DLS, NTA), protein composition (SDS-PAGE, mass spectrometry), endotoxin levels (LAL assay), and functional activity. Stability studies should determine optimal formulation parameters (buffer composition, pH, stabilizers) and storage conditions. Cost analysis should identify process steps contributing most significantly to production expenses, guiding focused optimization efforts.

What emerging technologies could advance understanding of STEAP2 structure-function relationships?

Emerging technologies offer promising avenues to deepen our understanding of STEAP2 structure-function relationships. Cryo-electron microscopy can now achieve near-atomic resolution of membrane proteins, potentially revealing the detailed structure of STEAP2 including substrate binding sites and conformational changes during catalysis. AlphaFold2 and related AI-based structure prediction tools provide increasingly accurate models that can guide experimental design. For dynamic studies, hydrogen-deuterium exchange mass spectrometry can map conformational changes upon substrate binding or protein-protein interactions. Single-molecule FRET approaches can monitor real-time conformational dynamics during the catalytic cycle. CRISPR-based saturating mutagenesis coupled with functional screening can systematically map structure-function relationships across the entire protein. Integration of these technologies with traditional biochemical approaches will provide comprehensive insights into how STEAP2's structure enables its functions in both normal physiology and pathological conditions.

How might STEAP2-VLPs be engineered for enhanced therapeutic outcomes?

Engineering STEAP2-VLPs for enhanced therapeutic outcomes presents multiple opportunities for innovation. Surface modification with targeting ligands (antibody fragments, peptides, aptamers) can direct VLPs to specific cell types or tissues, improving their biodistribution profile. Co-display of immunomodulatory molecules (such as CD40L or GITRL) alongside STEAP2 can enhance immune activation. For vaccine applications, incorporating universal T-helper epitopes can boost immunogenicity, while displaying multiple STEAP2 epitopes can generate broader immune responses less susceptible to escape mutations. Modifying the VLP core to enable controlled release of encapsulated adjuvants or drugs creates multifunctional therapeutic platforms. Material engineering approaches using biocompatible polymers can enhance stability under physiological conditions and extend circulation time. Evaluation of these engineered VLPs should systematically assess biodistribution, immunogenicity, therapeutic efficacy, and safety profiles in relevant preclinical models.

What opportunities exist for combining STEAP2-targeted therapies with other treatment modalities?

Combining STEAP2-targeted therapies with other treatment modalities offers synergistic opportunities for enhanced efficacy. Since STEAP2 promotes EMT via the PI3K/AKT/mTOR pathway , combination with pathway inhibitors (PI3K inhibitors, mTOR inhibitors) could yield synergistic effects by simultaneously targeting the protein and its downstream effectors. For immunotherapy combinations, STEAP2-VLP vaccines could sensitize tumors to immune checkpoint inhibitors by increasing tumor-infiltrating lymphocytes. In prostate cancer contexts, combining STEAP2-targeted therapies with androgen deprivation therapy may prevent resistance development. Given STEAP2's metalloreductase function , combinations with therapies that induce oxidative stress (certain chemotherapeutics, radiotherapy) could exploit redox imbalance to enhance cell death. Design of such combination studies should include careful sequencing and timing investigations, as the order of administration may significantly impact outcomes. Mechanistic studies should identify molecular markers predicting which patients would benefit most from specific combinations.

What role might STEAP2 play in cancer cell metabolism and microenvironment interactions?

STEAP2's metalloreductase activity suggests potential significant roles in cancer cell metabolism and microenvironment interactions that warrant further investigation. As a ferric reductase, STEAP2 likely contributes to cellular iron uptake , potentially supporting increased iron demand in rapidly proliferating cancer cells for DNA synthesis and mitochondrial function. Researchers should investigate whether STEAP2 expression correlates with markers of iron metabolism and whether iron chelation synergizes with STEAP2 inhibition. The ability to reduce copper suggests STEAP2 may support angiogenesis, as copper is required for endothelial cell proliferation and migration. Metabolomic analyses comparing STEAP2-expressing and STEAP2-knockdown cells could reveal broader metabolic dependencies. Co-culture experiments with cancer cells and stromal components (fibroblasts, immune cells, endothelial cells) can elucidate how STEAP2 influences the tumor microenvironment. Finally, in vivo studies using imaging mass cytometry or spatial transcriptomics could map relationships between STEAP2 expression patterns and metabolic or immunological features within the tumor microenvironment.